Trial · NCT00387023
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
NCT00387023, Not applicable, Completed, M.D. Anderson Cancer Center; results first posted 2013-11-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma. Trials, record NCT00387023. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00387023
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
- NCT number
- NCT00387023
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 12 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Non-Hodgkin's Lymphoma, Lymphoma
- Interventions
- Rituximab, Zevalin
- First posted
- 2006-10-12
- Last updated
- 2013-11-18
- Results first posted
- 2013-11-18
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Complete Response (CR) or Partial Response (PR) | 3 months | Tumor response to therapy measured by tumor size as measured radiographically at baseline and at three months from baseline. Tumor response classified as complete response (CR) or partial response (PR), or stable disease (SD), or progressive disease (PD) using International Workshop Standardized Response Criteria (IWC) for Non-Hodgkin's Lymphomas. If the orbital/ocular adnexal lymphoma was not evaluable radiographically, clinical evaluation using slit lamp biomicroscopy was used to assess PR or CR. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Complete Response (CR) or Partial Response (PR) | 3 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Complete Response (CR) or Partial Response (PR) | Zevalin + Rituximab | CR | 10 | participants | |
| Number of Participants With Complete Response (CR) or Partial Response (PR) | Zevalin + Rituximab | PR | 2 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Zevalin + Rituximab | 12 | |
| Overall Study | COMPLETED | Zevalin + Rituximab | 12 | |
| Overall Study | NOT COMPLETED | Zevalin + Rituximab | 0 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Transient Pancytopenia | Blood and lymphatic system disorders | Zevalin + Rituximab | 12 | 12 | |
| other | Anemia | Blood and lymphatic system disorders | Zevalin + Rituximab | 1 | 12 | |
| other | Fatigue | General disorders | Zevalin + Rituximab | 8 | 12 | |
| other | Increased Bruisability | General disorders | Zevalin + Rituximab | 7 | 12 | |
| other | Joint and Muscle Pain | Musculoskeletal and connective tissue disorders | Zevalin + Rituximab | 4 | 12 | |
| other | Nausea | Gastrointestinal disorders | Zevalin + Rituximab | 3 | 12 | |
| other | Headache | General disorders | Zevalin + Rituximab | 3 | 12 | |
| other | Fever | Infections and infestations | Zevalin + Rituximab | 1 | 12 | |
| other | Dizziness | General disorders | Zevalin + Rituximab | 1 | 12 | |
| other | Flushing | Skin and subcutaneous tissue disorders | Zevalin + Rituximab | 1 | 12 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Zevalin + Rituximab | ||
| Total, other adverse events | Zevalin + Rituximab | 12 | 12 |
| Total, serious adverse events | Zevalin + Rituximab | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00387023
GET https://conductscience.org/api/trials/v1/NCT00387023/registered